ストックスクリーナーアプリを入手
1.15
6.50%
-0.08
プレマーケット:
1.11
-0.04
-3.48%
An 2 Therapeutics Inc (ANTX) 最新ニュース
Relmada (NASDAQ: RLMD) posts 92% ORR in NMIBC as FDA supports two Phase 3 paths - Stock Titan
Rein Therapeutics (NASDAQ: RNTX) to resume Phase 2 IPF trial; U.S. enrollment at 20 sites - Stock Titan
2,541,781 Restricted Stock Units of Cognition Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-NOV-2025. - MarketScreener
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - Yahoo Finance
KYTX to host 8:00 a.m. ET call on KYV-101 Phase 2/3 results - Stock Titan
Kyverna Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to - GlobeNewswire
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - Yahoo Finance
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - Business Wire
RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous UrticariaSlideshow (NASDAQ:RAPT) 2025-10-20 - Seeking Alpha
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) - The Manila Times
RAPT Therapeutics to Report Topline Data from Phase 2 - GlobeNewswire
Monopar Therapeutics Inc. Announces Oral Presentation at AASLD 2025 for Phase 2 Study on Tiomolybdate Choline in Wilson Disease - Quiver Quantitative
Tvardi Therapeutics, Inc. Updates on Phase 2 REVERT Trial Results - TradingView
Denali Therapeutics Announces FDA Review Extension of BLA - GlobeNewswire
Aarvik Therapeutics Announces Investment by Laurus Labs in Aarvik Series Seed 2 Round - Business Wire
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewswire
Lyra Therapeutics Announces Clinical Plan for LYR-210 and - GlobeNewswire
Viking Therapeutics Stock: A Speculative Buy (NASDAQ:VKTX) - Seeking Alpha
Cellphire Therapeutics announces CRYPTICS Phase 2/3 Clinical Study Final Topline Results - GlobeNewswire
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension - GlobeNewswire
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate - Business Wire
Aarvik Therapeutics Announces Successful Series Seed 2 Financing Round - Business Wire
Viking Therapeutics: Overdue For Gains (NASDAQ:VKTX) - Seeking Alpha
United Therapeutics Corporation (UTHR) Phase 3 TETON-2 ResultsSlideshow - Seeking Alpha
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial - MSN
UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic - GlobeNewswire
Phase 2 Colorectal Cancer Trial Results: Leap Therapeutics' Sirexatamab Study Data Coming at ESMO 2025 - Stock Titan
Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data - Yahoo Finance
Allarity Therapeutics Presents New Phase 2 Clinical Data - GlobeNewswire
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis - PR Newswire
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe - GlobeNewswire
United Therapeutics' TETON-2 Trial Shows Success in IPF Treatment | UTHR Stock News - Stock Titan
skip to main content - United Therapeutics Investor Relations
Shareholders of Unicycive Therapeutics, Inc. Should Contact - GlobeNewswire
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer - PR Newswire
Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome - The Malaysian Reserve
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewswire
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes - FinancialContent
Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results - MSN
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 - The Manila Times
Kyverna Therapeutics to Highlight Interim Phase 2 Data from - GlobeNewswire
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA - GlobeNewswire
BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis - sg.finance.yahoo.com
Defence Therapeutics Inc. announced that it has received CAD 2 million in funding - MarketScreener
Institutional investors own a significant stake of 34% in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Yahoo
Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise - sg.finance.yahoo.com
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline - GlobeNewswire
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025 - Business Wire
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress - GlobeNewswire
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation - GlobeNewswire
Xilio Therapeutics Announces Initiation of Phase 2 Trial - GlobeNewswire
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - Yahoo Finance
Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan
0.64%
0.35%
大文字化:
|
ボリューム (24 時間):